LAKE FOREST, Calif.--(BUSINESS WIRE)--I-Flow Corporation (NASDAQ:IFLO) announced today the beginning of a human study in colorectal surgery to evaluate the antimicrobial benefits of the ON-Q® PainBuster System, its market-leading post-surgical pain relief brand. The study, which will include utilization of the ON-Q SilverSoaker® Antimicrobial Catheter, will assess the rate of surgical site infections in colorectal patients who get ON-Q therapy versus those who do not and will be conducted at a number of locations across the United States. Two of the initial sites will be in Atlanta and Omaha. The multi-center trial is expected to include more than 1,000 patients and take more than a year to complete.
